Thinking About Buying Mounjaro: The Decision Laid Out Clearly

Are you someone the licence covers?

The decision starts here, because eligibility is not simply a BMI number. The UK licence covers adults (not under-18s) with a BMI of 30 or above, or 27 or above if you have at least one weight-related condition such as high blood pressure, high cholesterol, type 2 diabetes, prediabetes or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance: 2.5 kg/m² lower for South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds, in line with NICE TA1026.

BMI is the starting point, not the whole picture. A prescriber also considers your medical history, any medicines you already take, and whether conditions like a history of pancreatitis or medullary thyroid carcinoma rule it out. Pregnancy, breastfeeding, and trying to conceive are all circumstances where Mounjaro is not recommended. The tirzepatide overview covers the clinical background in more depth if you want it.

Worth knowing: eligibility for a private prescription is assessed on the licensed criteria above. NHS access to Mounjaro is phased and, as of mid-2026, requires a higher BMI alongside several qualifying conditions. Most people exploring a purchase are doing so privately, because NHS waiting lists are long and the criteria are strict at this stage.

What the evidence actually says about results

Mounjaro's trial results are the strongest of any licensed weight-loss medicine currently available in the UK. SURMOUNT-1 (the pivotal phase 3 trial published in the New England Journal of Medicine) randomised 2,539 adults with obesity over 72 weeks. At the 15 mg dose, average weight reduction was around 20–21%, and if you are wondering how Mounjaro 2 mg fits into the dosing journey as the starting point for most people, that context matters when reading trial results. In the head-to-head SURMOUNT-5 trial, tirzepatide produced greater average weight loss than semaglutide 2.4 mg over 72 weeks.

Those figures come from people following a reduced-calorie diet and increased activity alongside the medicine, which is how it is licensed. The treatment is not a standalone fix. Our Mounjaro information page sets out the trial context in full, including what NICE concluded in its December 2024 appraisal.

If you have already started treatment and feel it is not working as expected, there are specific clinical reasons that can explain a plateau, the guide to weight changes on Mounjaro addresses those directly. Results vary between individuals, and no outcome can be guaranteed.

Side effects and safety: what to weigh up before you proceed

The most common side effects are gastrointestinal: nausea, diarrhoea, constipation, indigestion and burping. They are most noticeable when you first start or after a dose increase, and they usually ease within days to a couple of weeks. Fatigue, headache and injection-site reactions are also reported, and if you are unsure about technique, our guide on injecting Mounjaro above the belly button explains which sites work well and how to rotate them correctly. The NHS tirzepatide page lists these in plain language and is worth reading before you decide.

Some side effects require prompt medical attention. In January 2026, the MHRA issued a Drug Safety Update for GLP-1 medicines specifically flagging acute pancreatitis: if you develop severe, persistent stomach pain that radiates to the back, seek urgent help. Gallbladder problems and, in rare cases, allergic reactions have also been reported.

If you take an oral contraceptive pill, your prescriber will advise adding a non-oral method of contraception for the first four weeks of treatment and for four weeks after each dose increase, because Mounjaro can reduce pill absorption. Transdermal HRT (patches or gels rather than tablets) is worth discussing with your doctor for the same reason. And if you are having any surgical procedure, tell your anaesthetist you are taking it. None of this means Mounjaro is unsuitable for you; it means these conversations need to happen before you start.

How buying Mounjaro through a regulated UK pharmacy actually works

The only legal route to Mounjaro in the UK is a prescription following a clinical assessment. That rules out any seller offering it without one. The MHRA has seized around 20 million doses (roughly £45 million street value) of illegally traded weight-loss medicines in the UK, including counterfeit tirzepatide pens that reached patients. Checking any online pharmacy on the GPhC register takes under a minute and confirms whether it is legitimate.

At nume, the process runs like this: you complete a free consultation online, it is read the same day by a GPhC-registered Independent Prescriber (a real clinician, not software), and if you are clinically suitable your treatment is dispatched the same day if you order before midday. It arrives with DPD the next working day, tracked, in plain packaging, useful if you would rather it did not announce itself at the door. You can see the full details of what is included on the how to get Mounjaro page.

On cost: Mounjaro is priced per four-week pen and varies by dose. Since Eli Lilly raised UK list prices in September 2025, private market prices have typically ranged from around £149 to £375 per month depending on strength and provider. For a full picture of what goes into an honest price, the treatment cost breakdown is a useful read before you compare quotes. The right question is not which provider is cheapest, it is which one gives you a genuine supply chain, clinical review before every repeat, and aftercare when you need it.